N. Rastgoo

发表

Isolation of BNYVV coat protein-specific single chain Fv from a mouse phage library antibody.

M. Arbabi, Z. M. Jahromi, A. Salmanian, 2009, Hybridoma.

Role of CD47 in Hematological Malignancies

Hong Chang, Wenming Chen, N. Rastgoo, 2020, Journal of Hematology & Oncology.

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.

D. Reece, Hong Chang, E. Atenafu, 2018, Haematologica.

Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine.

A. Karami, K. Azadmanesh, M. Mahdavi, 2009, Cytokine.

MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.

Hong Chang, E. Zacksenhaus, Jian Wu, 2020, Cancer letters.

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma

Hong Chang, J. Hou, J. Abdi, 2017, Journal of Hematology & Oncology.

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Hong Chang, N. Rastgoo, Rosemarie Tremblay-Lemay, 2018, Journal of Hematology & Oncology.

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

R. Bejar, S. Howell, W. Rice, 2020 .

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies

Hong Chang, N. Rastgoo, Rosemarie Tremblay-Lemay, 2018, Biomarker Research.

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia

D. Bottomly, S. McWeeney, B. Druker, 2022, Molecular cancer therapeutics.

Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis

Hong Chang, Wenming Chen, J. Abdi, 2017, Journal of Hematology & Oncology.

Abstract CT239: Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas

R. Bejar, W. Rice, S. Howell, 2020 .

Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies

Hong Chang, N. Rastgoo, Aijun Liu, 2021, Biomarker research.

Green fluorescent-conjugated anti-CEA single chain antibody for the detection of CEA-positive cancer cells.

M. Arbabi, Z. M. Jahromi, N. Rastgoo, 2011, Hybridoma.

Restoring 3'-5' exonuclease activity of thermophilic Geobacillus DNA polymerase I using site-directed mutagenesis in active site.

S. Hosseinkhani, M. Sadeghizadeh, N. Rastgoo, 2009, Journal of biotechnology.

Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS

D. Reece, Hong Chang, J. Abdi, 2018, Leukemia.

Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells

Guoan Chen, Hong Chang, J. Abdi, 2019, BMC Cancer.

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

R. Bejar, S. Howell, W. Rice, 2020, Blood.

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies

Hong Chang, N. Rastgoo, Rosemarie Tremblay-Lemay, 2018, Biomarker Research.

Bacterial Expression and Functional Characterization of A Naturally Occurring Exon6-less Preprochymosin cDNA

G. R. Mianji, M. A. Ghahroudi, N. Rastgou, 2005 .